Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Hun Mo Ryoo
Randomized Phase III Trial of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients With Extensive-Disease Small Cell Lung Cancer
Cancer Research and Treatment
Cancer Research
Oncology
Related publications
A Phase I/Ii Study of Weekly Nab-Paclitaxel Plus Cisplatin in Chemotherapy-Naïve Patients With Advanced Non-Small-Cell Lung Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-Cell Lung Cancer
Clinical Lung Cancer
Cancer Research
Oncology
Respiratory Medicine
Pulmonary
Phase II Study of Docetaxel Alternating With Cisplatin in Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer
Anti-Cancer Drugs
Cancer Research
Oncology
Pharmacology
Safety and Efficacy of Docetaxel Plus Cisplatin Versus Cisplatin Concurrent With Radiation in Local Advanced Cervical Cancer: Midterm Results of a Phase III, Multicenter and Randomized Trial
International Journal of Radiation Oncology Biology Physics
Oncology
Radiology
Cancer Research
Radiation
Nuclear Medicine
Imaging
Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non–Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Phase III Study of Cisplatin With Pemtrexed or Vinorelbine Plus Concurrent Late Course Accelerated Hyperfractionated Radiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
Oncotarget
Oncology
P1.01-13 a Study of S-1 Plus Cisplatin in Patients With Advanced Non-Small-Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Phase II Trial of Cisplatin Plus Prednisone in Docetaxel-Refractory Castration-Resistant Prostate Cancer Patients
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Cisplatin Versus Cisplatin Plus Doxorubicin for Standard-Risk Hepatoblastoma
New England Journal of Medicine
Medicine